Vantrexa · SCLC · Japan · Pathologist · captured by James Whitfield on 30 Apr 2026 · reviewed by Dr. Elena Moretti on 02 May 2026
Verbatim as captured; never edited
Pathologist at Osaka University Hospital raised pd-l1 testing turnaround during a scientific exchange. They noted that colleagues in their network share the view.
Human-approved by Dr. Elena Moretti on 02 May 2026
PD-L1 testing turnaround: practice variation observed reported by pathologist (JP).
helixor-private-llm-2026.05 · generated 30 Apr 2026, 10:00 UTC
AI summary
PD-L1 testing turnaround raised by pathologist; suggest routing to HEOR.
Source spans used by the model
Pathologist at Osaka University Hospital raised pd-l1 testing turnaround during a scientific exchange. They noted that colleagues in their network share the view.
| Field | AI suggestion | Final (human-approved) |
|---|---|---|
| Category | Evidence gap | Evidence gap |
| Function | HEOR | HEOR |
| Priority | High | High |
Transparent weighted model; contribution = value ÷ 5 × weight
| Dimension | Value (1–5) | Weight | Contribution |
|---|---|---|---|
| Patient relevance | 4 | 20% | 16.0 |
| Strategic alignment | 4 | 20% | 16.0 |
| Scientific importance | 4 | 15% | 12.0 |
| Urgency | 4 | 15% | 12.0 |
| Novelty | 1 | 10% | 2.0 |
| Actionability | 4 | 10% | 8.0 |
| Confidence | 4 | 5% | 4.0 |
| Breadth of occurrence | 1 | 5% | 1.0 |
| Total | High 71 | ||
No audit events in sample data
Every model call on this record and its human outcome
No AI interactions in sample data
Current stage and the next allowed action
Who reviewed, what action, which function, what decision, what outcome, when closed
30 Apr 2026 · Dr. Javier Weber, Osaka University Hospital · MSL James Whitfield
Insight
Reviewed 02 May 2026 by Dr. Elena Moretti
Action
Publication project · David Chen · In progress
Decision
Outcome
Closure